A side benefit of having the FDA's ear while studying COVID would be highlighting Leronlimab with respect to Combo HIV and why it has not been approved. It seems unconscionable while people die to add other steps to it's approval. I think if the administration knew the extent of the ongoing litany of events and time frame they would make changes to the system. Not to mention all the people on Mono who have done well on L but have also passed while they ask for more testing.

This may well change the way the FDA goes about their clinical evaluations and trials.